secwatch / observer
8-K filed June 16, 2026, 4:34 PM ET ticker TVTX CIK 0001438533
leadership confidence high sentiment neutral materiality 0.40

Travere CRO William Rote to retire Feb 2027; CMO Inrig promoted to EVP, Head of R&D

Travere Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jula Inrig

Executive Vice President, Head of Research & Development and Chief Medical Officer
TVTX · Travere Therapeutics, Inc.
Effective
2026-07-01
Filed
June 16, 2026, 4:34 PM ET
Effective July 1, 2026, Dr. Inrig is being named Executive Vice President, Head of Research & Development and Chief Medical Officer.
Departed

William Rote

Chief Research Officer
TVTX · Travere Therapeutics, Inc.
Effective
2027-02-17
Successor
Jula Inrig
Filed
June 16, 2026, 4:34 PM ET
On June 12, 2026, William Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jula Inrig was named as Executive Vice President, Head of Research & Development and Chief Medical Officer at Travere Therapeutics, Inc..

Action
named
Role
Executive Vice President, Head of Research & Development and Chief Medical Officer
Exact text from the filing
Effective July 1, 2026, Dr. Inrig is being named Executive Vice President, Head of Research & Development and Chief Medical Officer.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

William Rote departed as Chief Research Officer at Travere Therapeutics, Inc..

Action
retire
Role
Chief Research Officer
Exact text from the filing
On June 12, 2026, William Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027
View on SEC.gov

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001438533-26-000048
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.